Foundayo's 28-Lb Menopause Win Expands Lilly's Obesity Rail-But the Real S-Curve Is Still Coming

Menopause data show Foundayo can reach a harder-to-treat obesity segment

Foundayo's menopause results look more like a franchise-expansion signal than a standalone weight-loss headline. In post-hoc analyses of more than 1,500 female participants, women on the highest dose lost up to 30.4 pounds in perimenopause and up to 28.2 pounds in post-menopause. In the broader ATTAIN-1 program, highest-dose participants lost an average of about 27 pounds. That matters because it suggests Lilly can engage a patient group that has often been underrepresented in obesity treatment discussions.